Now infants as young as nine months old can get protection against meningococcal disease after the US Food and Drug Administration gave its approval to Sanofi-Aventis' vaccines division, Sanofi Pasteur to expand its meningitis vaccine to include two doses for infants between 9 and 23 months.
The FDA revealed that it arrived at the decision since babies are more susceptible to the disease with the director of FDA's Center for Biologics Evaluation and Research, Dr Karen Midthun saying that the disease rate is highest among toddlers less than one year of age.
AdvertisementSanofi confirmed that it has been given the license to expand its meningitis vaccine, Menactra to include infants between 9 to 23 months old.
Menactra had so far been approved only for people over two years of age.
P One in Five Kids Victims of Bullying, Says CDC Report Mortality Risk High in IBD Patients With C.difficile Infection M
You May Also Like